Abdi İbrahim and Biogen Enter Strategic Partnership in Turkey

Abdi İbrahim, the leader of the Turkish pharmaceutical sector with a 113-year-old rooted history, announced its strategic partnership with Biogen. This collaboration with Biogen aims to increase access to innovative treatments in the field of neurology and rare diseases in Turkey.

Abdi İbrahim and Biogen Inc. announced that they have established a new strategic partnership for the distribution of Biogen pharmaceuticals used in the treatment of neurological and rare diseases in Turkey. Through this partnership, the expertise and strong resources of both companies will combine to deliver innovative treatments to patients in Turkey.

Abdi İbrahim Board Chairman Nezih Barut made the following assessment regarding the partnership: "We are proudly continuing our 113-year-old rooted legacy in the Turkish pharmaceutical sector, drawing strength from our patient-focused approach. As Biogen's business partner in Turkey, we aim to provide patients with the most advanced and current solutions in this field. This partnership will make a valuable contribution to the healthcare ecosystem by facilitating access to innovative treatments for both patients and healthcare professionals in Turkey."

Biogen Intercontinental Region President Fraser Hall stated: "As Biogen, we are committed to transforming patients' lives through groundbreaking scientific research and innovative treatments. Our partnership with Abdi İbrahim reflects our shared commitment to improving healthcare services and providing meaningful contributions to those fighting difficult-to-treat diseases."

Within the scope of this strategic partnership, Biogen and Abdi İbrahim will continue their efforts with determination to improve the quality of life of patients fighting neurological and rare diseases in Turkey and to advance the future of healthcare services.